浏览全部资源
扫码关注微信
德曲妥珠单抗对比恩美曲妥珠单抗二线治疗
HER2 阳性转移性乳腺癌的成本-效用分析Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for
HER2 -positive metastatic breast cancer- 中国药房 2024年35卷第2期 页码：204-209
- 作者机构：
中国药科大学国际医药商学院，南京 211198
- 作者简介：
硕士研究生。研究方向：医药产业经济与政策。 E-mail：15253894826@163.com
副教授，硕士生导师，博士。研究方向：医药产业经济与政策。E-mail：1020092084@cpu.edu.cn
- 基金信息：国家社会科学基金项目(22BGL252)
DOI：10.6039/j.issn.1001-0408.2024.02.14
中图分类号： R956;R979.1纸质出版日期：2024-01-30，
收稿日期：2023-07-29，
修回日期：2023-12-25，
扫 描 看 全 文
武亚楠,吴方,侯艳红.德曲妥珠单抗对比恩美曲妥珠单抗二线治疗HER2阳性转移性乳腺癌的成本-效用分析 Δ[J].中国药房,2024,35(02):204-209.
WU Yanan,WU Fang,HOU Yanhong.Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer[J].ZHONGGUO YAOFANG,2024,35(02):204-209.
武亚楠,吴方,侯艳红.德曲妥珠单抗对比恩美曲妥珠单抗二线治疗HER2阳性转移性乳腺癌的成本-效用分析 Δ[J].中国药房,2024,35(02):204-209. DOI： 10.6039/j.issn.1001-0408.2024.02.14.
WU Yanan,WU Fang,HOU Yanhong.Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer[J].ZHONGGUO YAOFANG,2024,35(02):204-209. DOI： 10.6039/j.issn.1001-0408.2024.02.14.
摘要
目的
2
评估德曲妥珠单抗（T-DXd）对比恩美曲妥珠单抗（T-DM1）二线治疗
HER2
阳性转移性乳腺癌的经济性，为临床用药方案的选择及医疗卫生决策提供依据。
方法
2
基于DESTINY-Breast03试验构建分区生存模型，以3周为循环周期，模拟至患者终身。以质量调整生命年（QALY）作为产出指标并计算增量成本-效果比（ICER），再利用敏感性分析验证基础分析结果的稳健性，以此来比较T-DXd与T-DM1二线治疗
HER2
阳性转移性乳腺癌的经济性。
结果
2
在以3倍我国2022年人均国内生产总值（GDP）为意愿支付阈值（257 094元/QALY）的前提下，使用T-DXd方案的患者在获得增量效用（0.69 QALYs）的同时也需要支付更多成本，ICER值为1 850 478.40元/QALY。单因素敏感性分析结果显示，对ICER影响较大的因素有无进展生存期状态效用值、T-DXd价格、成本贴现率等，但这些参数在合理范围内波动均不能使基础分析结果发生翻转。概率敏感性分析结果显示，当WTP的阈值上升为1 500 400元/QALY时，T-DXd方案具有经济性的概率为50%。情境分析结果也验证了基础分析结果的稳健性。
结论
2
在以3倍我国人均GDP为意愿支付阈值的前提下，与T-DM1方案相比，T-DXd二线治疗
HER2
阳性转移性乳腺癌不具有经济性。
Abstract
OBJECTIVE
2
To evaluate the cost-effectiveness of trastuzumab deruxtecan（T-DXd） versus trastuzumab emtansine （T-DM1） in the second-line treatment of
HER2
-positive metastatic breast cancer， and to provide a basis for the selection of clinical medication regimen and medical and health decisions.
METHODS
2
Based on the clinical trial DESTINY-Breast03， a partitioned survival model was constructed， with a cycle of 3 weeks as the simulation of patients’ lifetime. The incremental cost-effectiveness ratio （ICER） was calculated by using quality-adjusted life years （QALY） as output indicators， and sensitivity analysis was used to verify the robustness of the basic analysis results； the cost-effectiveness of the second-line treatment for
HER2
-positive metastatic breast cancer was compared between T-DXd and T-DM1.
RESULTS
2
Under the premise of taking 3 times China’s per capita gross domestic product （GDP） in 2022 as the willingness-to-pay threshold （257 094 yuan/QALY）， the T-DXd group also needed to pay more cost compared with T-DM1 group while obtaining incremental utility （0.69 QALYs）， and the ICER value was 1 850 478.40 yuan/QALY. The results of univariate sensitivity analysis showed that progression-free survival state utility value， T-DXd price， cost discount rate were factors that had a great influence on ICER value， but these parameters could not flip the basic analysis results within a reasonable range. In the probability sensitivity analysis， when the threshold of willingness-to-pay rose to 1 500 400 yuan/QALY， the probability of economic activity was 50% in the T-DXd regimen. The results of the scenario analysis also verified the robustness of the original research results.
CONCLUSIONS
2
Under the premise of 3 times China’s per capita GDP as the WTP threshold， compared with T-DM1， T-DXd is not cost-effective in the second-line treatment of
HER2
-positive metastatic breast cancer.
关键词
德曲妥珠单抗恩美曲妥珠单抗HER2阳性转移性乳腺癌分区生存模型成本-效用分析
Keywords
trastuzumab emtansineHER2-positive metastatic breast cancerpartitioned survival modelcost-utility analysis
references
SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.
LEI S Y，ZHENG R S，ZHANG S W，et al. Global patterns of breast cancer incidence and mortality：a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun，2021，41（11）：1183-1194.
CAO M M，LI H，SUN D Q，et al. Cancer burden of major cancers in China：a need for sustainable actions[J]. Cancer Commun，2020，40（5）：205-210.
SUN Y，LI W Q，LI A J，et al. Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative，HER2-positive breast cancer patients[J]. Cancer Manag Res，2019，11：3153-3162.
李阁，谷瑞雪，刘旭，等. Her-2阳性乳腺癌靶向治疗药物的研究进展[J]. 肿瘤学杂志，2020，26（1）：1-6.
LI G，GU R X，LIU X，et al. Research progress in treatment of Her-2-positive breast cancer with targeted agents[J]. J Chin Oncol，2020，26（1）：1-6.
CAMERON D，PICCART-GEBHART M J，GELBER R D，et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer：final analysis of the HERceptin Adjuvant （HERA） trial[J]. Lancet，2017，389（10075）：1195-1205.
HURVITZ S A，HEGG R，CHUNG W P，et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer：updated results from DESTINY-Breast03，a randomised，open-label，phase 3 trial[J]. Lancet，2023，401（10371）：105-117.
IM S A，GENNARI A，PARK Y H，et al. Pan-Asian adapted ESMO clinical practice guidelines for the diag-nosis，staging and treatment of patients with metastatic breast cancer[J]. ESMO Open，2023，8（3）：101541.
GRADISHAR W J，MORAN M S，ABRAHAM J，et al. NCCN guidelines® insights：breast cancer，version 4.2023[J]. J Natl Compr Canc Netw，2023，21（6）：594-608.
YANG J P，HAN J Q，ZHANG Y L，et al. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer[J]. Front Pharmacol，2022，13：924126.
ZHU Y W，LIU K，WANG M，et al. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer：a cost-effectiveness analysis[J]. Breast，2022，66：191-198.
刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：27-46.
LIU G E. China guidelines for pharmacoeconomic evaluations 2020[M]. Beijing：China Market Press，2020：27-46.
中国临床肿瘤学会.中国临床肿瘤学会（CSCO）乳腺癌诊疗指南 2023[Ｍ]. 北京：人民卫生出版社，2023：87.
Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology（CSCO）guidelines for the diagnosis and treatment of breast cancer 2023[M]. Beijing：People’s Medical Publishing House，2023：87.
SAURA C，OLIVEIRA M，FENG Y H，et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens：phase Ⅲ NALA trial[J]. J Clin Oncol，2020，38（27）：3138-3149.
WU Y，DONG Z，WANG J F，et al. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China：a cost-effectiveness analysis[J]. BMJ Open，2022，12（11）：e065299.
WANG H，ZENG C X，LI X，et al. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer[J]. Future Oncol，2019，15（2）：181-191.
高红婷，胡梦雪，贾琳琳，等. 信迪利单抗联合化疗一线治疗晚期或复发性非小细胞肺癌的成本-效用分析[J]. 中国药房，2022，33（15）：1854-1859.
GAO H T，HU M X，JIA L L，et al. Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced or recurrent non-small cell lung cancer[J]. China Pharm，2022，33（15）：1854-1859.
YANG Q，YU X X，ZHANG W. Health variations among breast-cancer patients from different disease states：evidence from China[J]. BMC Health Serv Res，2020，20（1）：1033.
DOI T，SHITARA K，NAITO Y，et al. Safety，pharmacokinetics，and antitumour activity of trastuzumab deruxtecan（DS-8201），a HER2-targeting antibody-drug conjugate，in patients with advanced breast and gastric or gastro-oesophageal tumours：a phase 1 dose-escalation study[J]. Lancet Oncol，2017，18（11）：1512-1522.
李欣. 从肿瘤药物的慈善赠药谈我国的患者援助项目[J]. 西部学刊，2022（13）：172-176.
LI X. Discussion on patient assistance projects in China from the perspective of charitable donation of tumor drugs[J]. J West，2022（13）：172-176.
OGITANI Y，AIDA T，HAGIHARA K，et al. DS-8201a，a novel HER2-targeting ADC with a novel DNA topoiso-merase Ⅰ inhibitor，demonstrates a promising antitumor efficacy with differentiation from T-DM1[J]. Clin Cancer Res，2016，22（20）：5097-5108.
0
浏览量
4
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies